BPC-157

Main evidence: Small human studies. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack summarizes preclinical and limited human evidence, reported protocols, safety caveats and Australian context for BPC-157.

What the sources say

BPC-157 is a synthetic 15-amino-acid peptide; most evidence in the supplied reviews is preclinical. Human reports are very small and low quality, and do not establish clinical efficacy or a reliable safety profile. (Small human studies; Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review", 2026-10-08)
A 2026 systematic review identified 3 human studies involving 30 participants and rated the evidence very low certainty; its authors advised against clinical use outside properly approved, high-quality trials. (Small human studies; Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review", 2026-10-08)
The 2026 WADA list prohibits BPC-157 at all times under S0 for athletes subject to that list; this anti-doping status is separate from therapeutic approval in Australia. (Educator material (not peer reviewed); WADA, 2026 Prohibited List, S0 Non-Approved Substances, 2026-01-01)
The systematic review summarizes a small human literature of low-quality, uncontrolled reports; those designs cannot establish efficacy or long-term safety. (Small human studies; Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review", 2026-10-08)
The 2026 systematic review includes a very small IV safety report; its small sample and brief follow-up cannot establish safety or a general dose range. (Small human studies; Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review", 2026-10-08)
A 2026 electronic-record preprint described 1,039 patients with documented use; among the 354 with recorded symptom direction, 79% were recorded as improved. The authors note selection bias, missing dose data and co-therapies, so this is not an efficacy rate. (Small human studies; Preprints.org, "Rising Use of Unapproved BPC-157 ('Wolverine Peptide') and Associated Patient-Reported Outcomes Curated from Clinical Notes", 2026-09-07)
The 2025 systematic review found that tendon, ligament, muscle, gut, skin and organ-protection claims are mainly supported by animal or cell studies; these findings do not establish benefits in people. (Animal studies; Vasireddi N et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review", 2025-07-31)
A phase 2 hamstring-injury study was listed as recruiting, with no results posted at the checked registry record; registration alone is not evidence of benefit. (Educator material (not peer reviewed); ClinicalTrials.gov, NCT07437547, BPC-HAMSTR phase 2 trial, 2026-02-27)
Absence of adverse events in the small reports summarized by the review does not establish safety; long-term effects and risks of unverified product identity, purity and sterility remain uncertain. (Small human studies; Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review", 2026-10-08)
Angiogenesis-related pathways are a theoretical concern discussed in the literature; the supplied evidence does not show that BPC-157 causes cancer in humans. (Animal studies; Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review", 2026-10-08)
The TGA warns generally that unapproved peptide products may have uncertain composition and sterility and have been associated with liver damage, severe allergic reactions and inflammation; these are class-level warnings, not proven BPC-157-specific event rates. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
The TGA/Chief Medical Officer names BPC-157 among unapproved peptide products not assessed for safety, quality or effectiveness and strongly advises Australians not to purchase or use such products, particularly online or from overseas. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
TGA guidance addresses importation, supply and advertising of unapproved therapeutic goods; exact legal outcomes depend on the applicable rules, exemptions and facts. This draft does not state that every possession or use circumstance is criminal. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
The 2026 WADA list includes BPC-157 under S0, prohibited at all times for athletes subject to that code. This anti-doping rule is not itself a full legal assessment of personal importation, possession or use in Australia. (Educator material (not peer reviewed); WADA, 2026 Prohibited List, S0 Non-Approved Substances, 2026-01-01)

Sources

Dosing, stacking and protocol details are not published here.